Subversive Capital in $43m series-B for Atai Life Sciences

Other investors in the round include Aperion Investment Group, Bail Capital and Pura Vida Investments founder Efrem Kamen.

The fresh capital will be invested in Atai's technology platform, the development of its existing drug pipeline, and the acquisition of additional compounds. In the future, the company plans to develop its own in-house drug discovery and development function.

Previous funding
Atai was founded by Christian Angermayer, Lars Wilde and Florian Brand, and was launched with an initial $12.6m seed round. The round saw participation from Christian Angermayer's family office Apeiron Investment Group, German investor HCS, Mike Novogratz's family office Galaxy Financial, and the co-founders of Compass Pathways, Ekaterina Malievskaia and George Goldsmith.

In September 2018, Atai completed a $24.4m series-A from business angels Thor Bjorgolfsson and Mike Novogratz.

Company
Founded in 2018, Atai uses big data and technology to accelerate the pace at which drugs to treat depression move through early-stage clinical trials. It is currently invested in Perception Neuroscience, Compass Pathways and Innoplexus, and employs five people.

People
Subversive Capital – Michael Auerbach (partner).
Atai Life Sciences – Florian Brand (CEO, co-founder); Christian Angermayer (founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Industrials
• Family Offices
• Venture
• Germany